Skip to main content
NewAmsterdam Pharma Company N.V. (NAMS)
NASDAQ: NAMS · Real-Time Price · USD
25.00
-0.76 (-2.95%)
Aug 14, 2025, 2:17 PM - Market open

Revenue by Product

Fiscal year is January - December.
Fiscal Year
 FY 2024 FY 2023 FY 2022
Period Ending
 Dec '24 Dec '23 Dec '22
Transformative Therapies for Cardio-metabolic Diseases
45.56M
Log In
Log In
Transformative Therapies for Cardio-metabolic Diseases Growth
223.37%
Log In
Log In

Revenue by Geography

Fiscal year is January - December.
Fiscal Year
 FY 2024 FY 2023 FY 2022
Period Ending
 Dec '24 Dec '23 Dec '22
Italy
45.56M
Log In
Log In
Italy Growth
223.37%
Log In
Log In